BUCHANG PHARMA(SH:603858) Cai Fu Zai Xian·2026-02-09 03:43Core Viewpoint - The recent share buyback by Buchang Pharma reflects the company's strong confidence in its intrinsic value and aims to boost market sentiment while ensuring stable returns for investors [1][2][3]. Group 1: Share Buyback Details - Buchang Pharma has initiated a new round of share buybacks, with the first phase completed through centralized bidding, demonstrating management's confidence in the company's value [1]. - The company plans to use its own funds and special loans from financial institutions for the buyback, with an estimated amount between 60 million to 120 million yuan and a maximum buyback price of 23.98 yuan per share [2]. - The first buyback was completed on February 2, 2026, with 2.176 million shares repurchased at prices ranging from 16.75 yuan to 17.12 yuan, totaling approximately 36.76 million yuan [2]. Group 2: Financial Performance and Growth - Buchang Pharma's 2025 annual performance forecast indicates a significant turnaround, with net profits expected to range from 320 million to 468 million yuan, marking a successful return to profitability [1]. - The company has distributed a total of 7.948 billion yuan in dividends since its listing and has spent 1.744 billion yuan on share buybacks and cancellations, exceeding the 3.9 billion yuan raised during its IPO [1]. - The core product matrix, including over 170 drugs included in the 2025 National Medical Insurance Directory, has established a strong foundation for sales growth [4]. Group 3: Strategic Implications of Buyback - The share buyback is expected to stabilize the stock price and enhance market confidence, particularly as the company's stock is currently at a relatively low level [3]. - The buyback will also be used for employee stock ownership plans or equity incentives, aligning the interests of core employees with the company's long-term development [3]. - The buyback strategy is part of a broader effort to optimize the company's capital structure and reduce financial risks, enhancing its resilience [3]. Group 4: Innovation and Market Expansion - Buchang Pharma has launched 17 new generic drugs in 2023, expanding into antiviral, anesthetic, and neurological markets, while also addressing gaps in its product offerings [5]. - The company is advancing into biopharmaceuticals and chemical drugs, with several first-class new drugs and biosimilars in the pipeline, which are crucial for long-term growth [5]. Group 5: Commitment to Social Responsibility - Buchang Pharma has contributed nearly 33 billion yuan in taxes nationwide, playing a significant role in local economic development [7]. - The company emphasizes its commitment to social responsibility and aims to contribute to the high-quality development of traditional Chinese medicine and the health of the nation [7].